MTOR and prostate carcinoma: One study showed that up to 80% of prostate cancer samples were positive for Pten-NOLC1 gene fusion in the prostate cancer samples6, while the other study showed that a panel of eight fusion genes including MAN2A1-FER, SLC45A2-AMACR, TRMT11-GRIK2, TMEM135-CCDC67, CCNH-C5orf30, LRRC59-FLJ60017, KDM4B-AC011523.2 and mTOR-TP53BP1 occurred in prostate cancer samples with various frequencies7.